Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- SpaceX shares fall as second lockup period ends
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
Intra-Cellular Therapies (ITCI) Prices 4.75M Offering at $24/Share
March 6, 2015 6:14 AM ESTIntra-Cellular Therapies (Nasdaq: ITCI) announced the pricing of its previously announced underwritten public offering of 4,750,000 shares of its common stock at a public offering price of $24.00 per share. All of the shares in the offering will be sold by Intra-Cellular Therapies. Net proceeds to... More
Intra-Cellular Therapies (ITCI) to Offer 4.25M Shares
March 4, 2015 7:14 AM ESTIntra-Cellular Therapies, Inc. (Nasdaq: ITCI) has commenced an underwritten public offering of 4,250,000 shares of its common stock. In connection with the offering, Intra-Cellular Therapies intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common... More
